File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy

TitleA phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy
Authors
Keywords5-Fluorouracil
Ifosfamide
Leucovorin
Nasopharyngeal carcinoma
Palliative chemotherapy
Recurrence
Issue Date2000
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca
Citation
European Journal Of Cancer, 2000, v. 36 n. 6, p. 736-741 How to Cite?
AbstractThe aim of this study was to evaluate the efficacy and toxicity of ifosfamide, 5-fluorouracil (5-FU) and leucovorin (IFL) as a second-line chemotherapy regimen in patients with recurrent undifferentiated nasopharyngeal carcinoma (NPC) previously treated with platinum/5-FU. Between June 1997 and February 1999, 18 patients were entered into the study. 3 patients had loco-regional recurrence, 12 had distant metastases and 3 had both loco-regional recurrence and distant metastases. All patients had previously received platinum/5-FU as adjuvant or palliative treatments. The IFL regimen consisting of ifosfamide 1.2 g/m2 (with mesna), 5-FU 375 mg/m2 and leucovorin 20 mg/m2 for 5 days and was repeated every 21 days. The dose of ifosfamide was escalated to 1.4 and 1.6 g/m2 in subsequent cycles according to the bone marrow toxicity, and the dose of 5-FU to 450 and 525 mg/m2 according to the severity of mucositis. Patients received a median of 3 cycles of IFL (range: 2-6), with a median total ifosfamide dose of 21 g/m2 (range: 13-46) and a median total 5-FU dose of 6.75 g/m2 (range: 4.1-14.7). The median follow-up was 10 months (range: 4-25). 9 patients (50%) achieved a partial response and 1 patient (6%) achieved a complete response, with an overall response rate of 56% (95% confidence interval (CI): 32-80%). For those patients who responded to IFL, 8 had subsequent disease progression on follow-up, with a median response duration of 7.1 months (95% CI: 5.3-8.9). The median time to progression for all patients was 6.5 months (95% CI: 4.2-8.7). 12 patients are still alive with an estimated 1-year survival probability rate of 51%. Treatments were well tolerated, only 1 patient had grade 3 emesis. None of the patients had grade 3/4 anaemia, leucopenia or thrombocytopenia, although IFL was discontinued in 1 patient because of persisting thrombocytopenia. IFL is an effective second-line regimen in patients with recurrent NPC and is well tolerated with mild toxicity. Combining platinum and IFL in chemonaive patients may further improve the overall response rate and duration and is worth investigating in future trials. Copyright (C) 2000 Elsevier Science Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/150755
ISSN
2015 Impact Factor: 6.163
2015 SCImago Journal Rankings: 3.152
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChua, DTTen_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorAu, GKHen_HK
dc.contributor.authorChoy, Den_HK
dc.date.accessioned2012-06-26T06:09:56Z-
dc.date.available2012-06-26T06:09:56Z-
dc.date.issued2000en_HK
dc.identifier.citationEuropean Journal Of Cancer, 2000, v. 36 n. 6, p. 736-741en_HK
dc.identifier.issn0959-8049en_HK
dc.identifier.urihttp://hdl.handle.net/10722/150755-
dc.description.abstractThe aim of this study was to evaluate the efficacy and toxicity of ifosfamide, 5-fluorouracil (5-FU) and leucovorin (IFL) as a second-line chemotherapy regimen in patients with recurrent undifferentiated nasopharyngeal carcinoma (NPC) previously treated with platinum/5-FU. Between June 1997 and February 1999, 18 patients were entered into the study. 3 patients had loco-regional recurrence, 12 had distant metastases and 3 had both loco-regional recurrence and distant metastases. All patients had previously received platinum/5-FU as adjuvant or palliative treatments. The IFL regimen consisting of ifosfamide 1.2 g/m2 (with mesna), 5-FU 375 mg/m2 and leucovorin 20 mg/m2 for 5 days and was repeated every 21 days. The dose of ifosfamide was escalated to 1.4 and 1.6 g/m2 in subsequent cycles according to the bone marrow toxicity, and the dose of 5-FU to 450 and 525 mg/m2 according to the severity of mucositis. Patients received a median of 3 cycles of IFL (range: 2-6), with a median total ifosfamide dose of 21 g/m2 (range: 13-46) and a median total 5-FU dose of 6.75 g/m2 (range: 4.1-14.7). The median follow-up was 10 months (range: 4-25). 9 patients (50%) achieved a partial response and 1 patient (6%) achieved a complete response, with an overall response rate of 56% (95% confidence interval (CI): 32-80%). For those patients who responded to IFL, 8 had subsequent disease progression on follow-up, with a median response duration of 7.1 months (95% CI: 5.3-8.9). The median time to progression for all patients was 6.5 months (95% CI: 4.2-8.7). 12 patients are still alive with an estimated 1-year survival probability rate of 51%. Treatments were well tolerated, only 1 patient had grade 3 emesis. None of the patients had grade 3/4 anaemia, leucopenia or thrombocytopenia, although IFL was discontinued in 1 patient because of persisting thrombocytopenia. IFL is an effective second-line regimen in patients with recurrent NPC and is well tolerated with mild toxicity. Combining platinum and IFL in chemonaive patients may further improve the overall response rate and duration and is worth investigating in future trials. Copyright (C) 2000 Elsevier Science Ltd.en_HK
dc.languageengen_US
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejcaen_HK
dc.relation.ispartofEuropean Journal of Canceren_HK
dc.subject5-Fluorouracilen_HK
dc.subjectIfosfamideen_HK
dc.subjectLeucovorinen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectPalliative chemotherapyen_HK
dc.subjectRecurrenceen_HK
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFluorouracil - Administration & Dosageen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshIfosfamide - Administration & Dosageen_US
dc.subject.meshLeucovorin - Administration & Dosageen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNasopharyngeal Neoplasms - Drug Therapy - Radiographyen_US
dc.subject.meshNeoplasm Metastasisen_US
dc.subject.meshNeoplasm Recurrence, Local - Drug Therapyen_US
dc.subject.meshPlatinum Compounds - Administration & Dosageen_US
dc.subject.meshTomography, X-Ray Computeden_US
dc.titleA phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapyen_HK
dc.typeArticleen_HK
dc.identifier.emailChua, DTT: dttchua@hkucc.hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.authorityChua, DTT=rp00415en_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0959-8049(00)00008-3en_HK
dc.identifier.pmid10762745-
dc.identifier.scopuseid_2-s2.0-0034106426en_HK
dc.identifier.hkuros52957-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034106426&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue6en_HK
dc.identifier.spage736en_HK
dc.identifier.epage741en_HK
dc.identifier.isiWOS:000086811800014-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChua, DTT=7006773480en_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridSham, JST=7101655565en_HK
dc.identifier.scopusauthoridAu, GKH=7003748615en_HK
dc.identifier.scopusauthoridChoy, D=7102939127en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats